cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Sarepta Therapeutics Inc
23 own
27 watching
Current Price
$117.12
$0.16
(0.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
7,391.12M
52-Week High
52-Week High
159.89000
52-Week Low
52-Week Low
55.25000
Average Volume
Average Volume
0.42M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization7,391.12M
icon52-Week High159.89000
icon52-Week Low55.25000
iconAverage Volume0.42M
iconDividend Yield--
iconP/E Ratio--
What does the Sarepta Therapeutics Inc do?
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; and collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Sarepta Therapeutics Inc make?
News & Events about Sarepta Therapeutics Inc.
Business Wire
9 months ago
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). Sarepta received a payment of $102 million upon completion of the sale. Sarepta was awarded...
Business Wire
9 months ago
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023 at 11:00 a.m. E.T. The fireside chat will be held...
TipRanks Financial Blog
10 months ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT Research Report), Int... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT Research Report), Intercept...
Business Wire
10 months ago
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of...
Benzinga
11 months ago
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Sarepta Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Sarepta Therapeutics Inc shares?
plus_minus_icon
How can I buy Sarepta Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Sarepta Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Sarepta Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Sarepta Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Sarepta Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Sarepta Therapeutics Inc?
plus_minus_icon
What percentage is Sarepta Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Sarepta Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$117.12
$0.16
(0.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ascendis Pharma A/S
Ascendis Pharma A/S
$144.83
$2.73 (1.92 %)
FibroGen Inc
FibroGen Inc
$1.07
$-0.07 (-6.14 %)
Galapagos NV
Galapagos NV
$29.45
$0.38 (1.31 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$12.94
$0.05 (0.39 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ascendis Pharma A/S
Ascendis Pharma A/S
$144.83
$2.73 (1.92 %)
FibroGen Inc
FibroGen Inc
$1.07
$-0.07 (-6.14 %)
Galapagos NV
Galapagos NV
$29.45
$0.38 (1.31 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$12.94
$0.05 (0.39 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00